
    
      This randomized, double-blind, placebo and active controlled Phase I study is intended to
      study the effects of a live-attenuated vaccine against influenza A H1N1. Part 1 of this study
      will enroll 75 participants at a single site. Participants will be randomized in a 2:2:1
      ratio to receive one dose each of either CodaVax-H1N1, FluZone quadrivalent, or placebo. This
      study is conducted during the influenza "off season" in Australia. Part 2 of the study will
      enroll an 50 additional participants randomized to receive either CodaVax-H1N1 at a higher
      dose or placebo (40:10).
    
  